Pay in 4 interest-free payments of $6.09 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jdar E, Leiter LA, et al
Exenatide-induced depression in a geriatric patient
FDA Kapitza C, Nosek L, Jensen L, et al
Tapering versus abrupt cessation The clinical trials did not specifically study tapering protocols, but physiological principles suggest a gradual dose reduction may produce a smoother transition than abrupt cessation
Long-term health, and limitations GLP-1 weight loss drugs are not cancer prevention medications, and they are not designed to be taken forever
The results were extraordinary: Retatrutide 1mg: 42.9% reduction in liver fat at 24 weeks Retatrutide 4mg: 57.0% reduction Retatrutide 8mg: 81.4% reduction Retatrutide 12mg: 82.4% reduction Placebo: 0.3% increase By 48 weeks, 89% of participants on 8mg and 93% on 12mg had achieved normal liver fat levels (below 5%)
